Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding critical drug pipeline milestones or tracking when Corvus Pharmaceuticals’ executives buy shares often means wading through hundreds of pages across multiple SEC forms. Clinical-stage biotech disclosures are dense: R&D burn rates hide inside footnotes, milestone payments get buried in 8-K exhibits, and equity grants change every quarter. Many investors still Google “Corvus Pharmaceuticals SEC filings explained simply” and hit a wall of jargon—until now.
Stock Titan delivers the solution. Our AI-powered summaries turn the Corvus Pharmaceuticals annual report 10-K simplified into a handful of clear paragraphs, spotlight every line item in the Corvus Pharmaceuticals quarterly earnings report 10-Q filing that affects cash runway, and flag each Corvus Pharmaceuticals insider trading Form 4 transactions within minutes of posting. Need to know about a study halt or partnership reveal? We send alerts the moment a Corvus Pharmaceuticals 8-K material events explained document lands on EDGAR. Even the Corvus Pharmaceuticals proxy statement executive compensation section is decoded, linking pay to clinical progress. It’s all part of understanding Corvus Pharmaceuticals SEC documents with AI—without sifting through technical language.
Whether you’re conducting Corvus Pharmaceuticals earnings report filing analysis or just checking sentiment, you’ll find every form in one place—updated in real time. Investors routinely use the platform to:
- Monitor Corvus Pharmaceuticals Form 4 insider transactions real-time for buying or selling signals
- Review trial spending trends inside each 10-Q
- Compare executive stock transactions Form 4 against upcoming catalysts
Form 4 filing for Corvus Pharmaceuticals (CRVS) dated 07/01/2025 details insider transactions by OrbiMed-affiliated entities.
- Warrant exercise: On 06/27/2025, OrbiMed Private Investments V, LP ("OPI V") exercised 1,397,684 common stock warrants at $3.50 per share.
- Cashless settlement: The transaction was executed on a cashless basis. To satisfy the $4.9 million aggregate exercise price, the issuer withheld 1,176,332 warrant shares, issuing the remaining 221,352 shares to OPI V.
- Open-market disposition: Table I also shows a Code "S" disposal of the same 1,176,332 shares at an average price of $4.1586.
- Post-transaction holdings: OrbiMed’s indirect beneficial ownership declined from 8,341,338 to 7,165,006 common shares, but it remains a >10% shareholder and board-represented director.
- Control structure: OPI V is controlled by OrbiMed Capital GP V LLC (general partner) and OrbiMed Advisors LLC (managing member). Each entity disclaims beneficial ownership except to the extent of pecuniary interest.
The filing signals routine warrant housekeeping before the 06/30/2025 expiry rather than a strategic shift. The cashless feature limits share issuance to 221,352 new shares, a modest dilution relative to OrbiMed’s prior stake. Nonetheless, the simultaneous disposition reduces OrbiMed’s ownership by roughly 14%, which investors may view as a slight negative sentiment indicator.
Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 insider activity dated 06/27/2025
Director and 10% owner Peter A. Thompson, acting through OrbiMed Private Investments V, LP (OPI V), exercised 1,397,684 common stock warrants at $3.50 just before their 06/30/2025 expiry. The warrants were settled on a cashless basis: the issuer withheld 1,176,332 shares (coded “S”) to fund the exercise, and issued 221,352 new shares to OPI V (coded “X”). Following the transactions, Thompson/OPI V’s indirect beneficial ownership stands at 7,165,006 shares.
The filing shows a small net increase in insider ownership and a modest share-count expansion for the company. No open-market sales were reported; the disposition reflects internal share withholding rather than a public sale.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
What is the core focus of Corvus Pharmaceuticals?
What is soquelitinib and its significance?
Which therapeutic areas are addressed by Corvus’ pipeline?
How does ITK inhibition work as a therapeutic strategy?
What makes Corvus Pharmaceuticals unique in its field?
How is clinical research structured at Corvus?
What collaborations has Corvus Pharmaceuticals engaged in?
How is the company addressing the competitive landscape?
